1.Alternative Name:4-1BB,TNFRSF9;4-1BB ligand receptor; 41BB; 4-1BB; CD137 antigen; CD137; CD137MGC2172; CDw137; FLJ43501; ILA; ILAhomolog of mouse 4-1BB; induced by lymphocyte activation (ILA); interleukin-activated receptor, homolog of mouse Ly63; receptor protein 4-1BB; T cell antigen ILA; T-cell antigen 4-1BB homolog; T-cell antigen ILA; TNFRSF9; tumor necrosis factor receptor superfamily member 9; tumor necrosis factor receptor superfamily, member 9
2.Target:CD137
3.Source:Cynomolgus CD137 was expressed from CHO with human IgG1 FC at the C-terminal
4.Sequence:Leu24-Gln186
5.Protein structure:A9YYE7hFC
6.Molecular Characterization:The protein has a calculated MW of 43kDa.The reducing (R) heterodimer protein migrates as 50-70 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .
11.SDS-PAGE
Determined by SDS-PAGE, the purity of the protein is greater than 95%.
12.SEC-HPLC
Determined by SEC-HPLC, the purity of the protein is greater than 90%.
13.ELISA
When Recombinant Cynomolgus CD137/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD137(Utomilumab) that produces 50% of the optimal binding response is approximately 0.4ug/ml.
...
产品展厅
